WT1 and Kaposi's sarcoma: Given that WT1 peptide vaccines have been found to be safe and induce clinical and immunological responses [37,85], this approach may be attractive for use as a therapeutic vaccine against KS, especially in chemotherapy-resistant or recurrent cases as adjunctive therapy or in low grade disease which may be controlled without the need for chemotherapy.